We were delighted to talk with Dr. David Rosmarin (Tufts Medical Center, Boston, MA, USA) to discuss the efficacy and safety findings of the TRuE-V1 and TRuE-V2 studies, investigating ruxolitinib cream monotherapy for the treatment of vitiligo.
The abstract ‘Efficacy and Safety of Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo: Results From Two 52-Week Phase 3 Studies’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD. Â
Questions
- What is the rationale for the use of ruxolitinib cream in the treatment of vitiligo? (0:13)
- What were the aims, design and eligibility criteria of the TRuE-V1 and TRuE-V2 studies? (0:45)
- What were the efficacy and safety findings of these studies? (2:00)
- If approved, what will be the impact of ruxolitinib cream on the treatment of patients with vitiligo? (3:16)
- Which patients are most likely to respond to this treatment? (3:40)
- What future studies are planned? (4:24)
Disclosures: David Rosmarin discloses consulting for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; grant/ research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and participating in speaker’s bureaus for AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
